Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis.
duration of protection
immunodeficiency
risk group
systematic review
yellow fever vaccine
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
19 12 2022
19 12 2022
Historique:
received:
08
04
2022
pubmed:
21
7
2022
medline:
22
12
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
The duration of protection after a single dose of yellow fever vaccine is a matter of debate. To summarize the current knowledge, we performed a systematic literature review and meta-analysis. Studies on the duration of protection after 1 and ≥2 vaccine doses were reviewed. Data were stratified by time since vaccination. In our meta-analysis, we used random-effects models. We identified 36 studies from 20 countries, comprising more than 17 000 participants aged 6 months to 85 years. Among healthy adults and children, pooled seroprotection rates after single vaccination dose were close to 100% by 3 months and remained high in adults for 5 to 10 years. In children vaccinated before age 2 years, the seroprotection rate was 52% within 5 years after primary vaccination. For immunodeficient persons, data indicate relevant waning. The extent of waning of seroprotection after yellow fever vaccination depends on age and immune status at primary vaccination.
Identifiants
pubmed: 35856638
pii: 6646957
doi: 10.1093/cid/ciac580
pmc: PMC9761887
doi:
Substances chimiques
Yellow Fever Vaccine
0
Antigens, Viral
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2266-2274Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. C. D. reports an unpaid position as Chairman of the WHO EYE (Eliminating Yellow Fever Epidemics) Laboratory Technical Working Group. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
PLoS Negl Trop Dis. 2018 Jun 4;12(6):e0006538
pubmed: 29864115
Front Immunol. 2020 Oct 08;11:577751
pubmed: 33133096
Vaccine. 1995 Jan;13(1):109-11
pubmed: 7598769
Emerg Infect Dis. 2019 Aug;25(8):1511-1521
pubmed: 31298654
Am J Trop Med Hyg. 2013 Jan;88(1):172-7
pubmed: 23208880
Clin Infect Dis. 2018 Mar 19;66(7):1099-1108
pubmed: 29140432
J Travel Med. 2021 Dec 29;28(8):
pubmed: 34401911
Antiviral Res. 2019 Feb;162:1-4
pubmed: 30529359
Appl Microbiol. 1973 Apr;25(4):539-44
pubmed: 4633476
Hum Vaccin. 2006 Mar-Apr;2(2):60-7
pubmed: 17012873
Vaccine. 2019 Aug 14;37(35):5129-5135
pubmed: 31171393
Vaccine. 2020 Apr 16;38(18):3411-3421
pubmed: 32192811
Lancet. 2021 Jan 9;397(10269):119-127
pubmed: 33422245
Am J Trop Med Hyg. 2013 Sep;89(3):434-44
pubmed: 24006295
J Travel Med. 2019 Jun 11;26(5):
pubmed: 31150098
Vaccine. 2015 May 11;33(20):2301-6
pubmed: 25843268
Bull World Health Organ. 2001;79(11):1056-9
pubmed: 11731813
Hum Vaccin. 2010 Nov;6(11):906-14
pubmed: 20864814
Hum Vaccin Immunother. 2016;12(2):491-502
pubmed: 26360663
Front Immunol. 2020 Jul 17;11:1382
pubmed: 32765496
Am J Trop Med Hyg. 2002 May;66(5):533-41
pubmed: 12201587
Nat Microbiol. 2016 Sep 19;1:16164
pubmed: 27642668
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95
pubmed: 26361176
PeerJ. 2020 Feb 27;8:e8601
pubmed: 32149023
J Travel Med. 2019 Oct 14;26(7):
pubmed: 30476151
Wkly Epidemiol Rec. 2013 Jul 5;88(27):269-83
pubmed: 23909008
NPJ Vaccines. 2020 Jul 6;5(1):54
pubmed: 32655896
Pediatr Infect Dis J. 2016 Oct;35(10):1140-7
pubmed: 27254034
AIDS. 2018 Oct 23;32(16):2291-2299
pubmed: 30096071
Trop Dis Travel Med Vaccines. 2020 Jan 10;6:1
pubmed: 31938550
Lancet Infect Dis. 2019 Dec;19(12):1363-1370
pubmed: 31543249
J Travel Med. 2018 Jan 1;25(1):
pubmed: 30462249
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
J Clin Virol. 2015 Mar;64:160-73
pubmed: 25453327
PLoS One. 2011;6(12):e27753
pubmed: 22163273
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
BMC Infect Dis. 2014 Jul 15;14:391
pubmed: 25022840
PLoS One. 2008 Apr 23;3(4):e1993
pubmed: 18431480
Vaccine. 1999 Mar 5;17(9-10):1042-6
pubmed: 10195613
J Infect Dis. 2020 Jun 11;221(12):2018-2025
pubmed: 31545367
Mem Inst Oswaldo Cruz. 2015 Sep;110(6):771-80
pubmed: 26517656
Cad Saude Publica. 2020 Nov 02;36Suppl 2(Suppl 2):e00008520
pubmed: 33146313
Expert Rev Vaccines. 2016 Dec;15(12):1519-1533
pubmed: 27267203
Arthritis Care Res (Hoboken). 2013 Sep;65(9):1522-8
pubmed: 23554297
Vaccine. 2020 Apr 23;38(19):3610-3617
pubmed: 31911033
Am J Trop Med Hyg. 1999 Jun;60(6):1045-50
pubmed: 10403341
Am J Trop Med Hyg. 2005 Feb;72(2):189-97
pubmed: 15741556
PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005219
pubmed: 27941965
Mem Inst Oswaldo Cruz. 2018 Feb;113(2):135-137
pubmed: 29185596
Rev Saude Publica. 2004 Oct;38(5):671-8
pubmed: 15499438
Pediatr Infect Dis J. 1997 Dec;16(12):1177-9
pubmed: 9427466
Front Immunol. 2019 Sep 26;10:2192
pubmed: 31616412